<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Murphy, Sabina A.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Ezetimibe Plus Simvastatin More Beneficial Than Simvastatin Alone in Reducing Recurrent Cardiovascular Events</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-04-24 09:14:01</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">18-19</style></pages><abstract><style  face="normal" font="default" size="100%">Results from IMPROVE-IT showed that adding ezetimibe to statin therapy with simvastatin significantly reduced the primary end point in moderate- to high-risk patients stabilized after acute coronary syndromes. A new analysis from IMPROVE-IT showed that the number of first and recurrent primary end point events was also reduced with combination therapy vs monotherapy over the median 6-year follow-up.</style></abstract><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>